PMID- 10613751
OWN - NLM
STAT- MEDLINE
DCOM- 20000113
LR  - 20061115
IS  - 0270-9139 (Print)
IS  - 0270-9139 (Linking)
VI  - 31
IP  - 1
DP  - 2000 Jan
TI  - Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis 
      C.
PG  - 230-4
AB  - The immunogenicity of hepatitis B vaccine is unknown for patients with chronic 
      hepatitis C, although hepatitis B vaccination is highly recommended in these 
      patients. We therefore studied in a prospective open trial of 59 patients with 
      chronic hepatitis C (mean age 42 years, hepatitis C for >10 years, Child-Pugh 
      score < or = 5) and 58 healthy hospital staff persons the rate of nonresponse 
      (anti-HBs <10 mIU/mL at 9 months) to recombinant hepatitis B vaccine (Gen 
      H-B-Vax(R),10 microg intradeltoidal at month 0, 1, and 6). Nonresponse was 
      observed in 18/59 (31%) patients with chronic hepatitis C and 5/58 (9%) healthy 
      staff persons (P <.005) (vs. 7% in historical controls; P <.005), low response 
      (anti-HBs 10-99 mIU/mL) in 19% of patients with chronic hepatitis C and 17% of 
      staff persons. High-dose booster vaccination led to seroconversion in 12/15 (80%) 
      of primary nonresponders. Primary nonresponse to HB vaccine was related neither 
      to presence of early-stage liver cirrhosis nor magnitude of serum hepatitis C 
      virus (HCV) RNA concentration, nor explained by the presence of human leukocyte 
      antigen (HLA) types (B8 DR3, B44, DR7, DQ2) predisposing to low antibody response 
      to hepatitis B surface antigen. The rate of primary nonresponse to the standard 
      regimen of recombinant hepatitis B vaccine is surprisingly high in patients with 
      longstanding chronic hepatitis C. Therefore, the antibody to HBV surface antigen 
      (anti-HBs) titer response should be determined in these patients. Depending on 
      the response titer, higher booster doses may be required to achieve and maintain 
      seroprotection in these patients.
FAU - Wiedmann, M
AU  - Wiedmann M
AD  - Department of Medicine II, University of Leipzig, Germany.
FAU - Liebert, U G
AU  - Liebert UG
FAU - Oesen, U
AU  - Oesen U
FAU - Porst, H
AU  - Porst H
FAU - Wiese, M
AU  - Wiese M
FAU - Schroeder, S
AU  - Schroeder S
FAU - Halm, U
AU  - Halm U
FAU - Mossner, J
AU  - Mossner J
FAU - Berr, F
AU  - Berr F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
RN  - 0 (Hepatitis B Antibodies)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Vaccines, Synthetic)
SB  - IM
CIN - Hepatology. 2000 Aug;32(2):444-5. PMID: 10960283
MH  - Adult
MH  - Aged
MH  - Female
MH  - Hepatitis B/prevention & control
MH  - Hepatitis B Antibodies/blood
MH  - Hepatitis B Surface Antigens/immunology
MH  - Hepatitis B Vaccines/*immunology
MH  - Hepatitis C, Chronic/*immunology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Vaccination
MH  - Vaccines, Synthetic/*immunology
EDAT- 1999/12/29 00:00
MHDA- 1999/12/29 00:01
CRDT- 1999/12/29 00:00
PHST- 1999/12/29 00:00 [pubmed]
PHST- 1999/12/29 00:01 [medline]
PHST- 1999/12/29 00:00 [entrez]
AID - S0270913900755170 [pii]
AID - 10.1002/hep.510310134 [doi]
PST - ppublish
SO  - Hepatology. 2000 Jan;31(1):230-4. doi: 10.1002/hep.510310134.